LBA4_PR - Combi-V: a Randomised, Open-Label, Phase III Study Comparing the Combination of Dabrafenib (D) and Trametinib (T) with Vemurafenib (V) As First-Line Therapy in Patients (Pts) with Unresectable or Metastatic Braf V600E/K Mutation-Positive Cutaneous Melanoma
| Autor: | Robert, C., Karaszewska, B., Schachter, J., Rutkowski, P., Mackiewicz, A., Stroiakovski, D., Lichinitser, M., Dummer, R., Grange, F., Mortier, L., Chiarion-Sileni, V., Drucis, K., Krajsova, I., Hauschild, A., Sun, P., Rubin, S.D., Legos, J., Crist, W.A., Little, S.M., Schadendorf, D. |
|---|---|
| Zdroj: | In Annals of Oncology September 2014 25 Supplement 4:v1-v1 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|